Maprotiline: an antidepressant with an unusual pharmacological profile.
The DOI matches its Crossref record.
Abstract
Maprotiline, which differs from other typical tricyclic antidepressants for its tetracyclic structure, is a highly selective inhibitor of norepinephrine reuptake. Despite its in vitro and in vivo inhibitory activity on NE uptake, 21 repeated daily injections of maprotiline (20 mg/kg i.p.) neither attenuated the norepinephrine-stimulated cAMP accumulation nor reduced the number of beta adrenergic recognition sites in rat frontal cortex. Also, the number of brain serotonin2 recognition sites labeled by [3H]ketanserin remained virtually unchanged in rats receiving 21 daily injections of maprotiline. [3H]Desmethylimipramine and [3H]mianserin specific binding sites were also unmodified by repeated maprotiline injections. However, after 3 weeks of daily administrations, maprotiline elicited a significant decrease in the number of [3H]flunitrazepam binding sites and a decrease in the apparent affinity of [3H]beta-carboline ethylester binding to crude synaptic membranes prepared from hippocampal and hypothalamic homogenates. These changes appear to be unrelated to modifications in the concentration of endogenous gamma-aminobutyric acid present in the membrane preparation, since the addition of 100 microM bicuculline to the incubation mixture decreases [3H]flunitrazepam binding to the same extent in saline- and maprotiline-treated rats. It is suggested that repeated maprotiline injections may elicit an increase in the hypothalamic and hippocampal tissue levels of an endogenous substance(s) which binds to the benzodiazepine/beta-carboline recognition sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
GABAergic dysfunction in mood disorders
Brambilla, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001362 · Cited by 553
The effects of chronic antidepressant treatment in an animal model of anxiety
Bodnoff, S., Suranyi-Cadotte, B., Aitken, D., Quirion, R., & Meaney, M. (1988) · Psychopharmacology · doi:10.1007/bf00181937 · Cited by 437
Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test
Farzin, D., & Mansouri, N. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.08.005 · Cited by 171
“h-Carbolines bind with high affinity to benzodiazepine site of the g-aminobutyric acid type A (GABAA) receptors as inverse agonists; some possess anxiogenic character and others display anxiolytic properties, depending on the dose (Muller et al., 1981; Rommelspacher et al., 1981, 1985; Prado de Carvalho et al., 1983;…”
BackgroundMoura, D. J., Richter, M. F., Boeira, J. M., Pegas Henriques, J. A., & Saffi, J. (2007) · Mutagenesis · doi:10.1093/mutage/gem016 · Cited by 152
Metadata
- Authors
- Barbaccia, M. L., Ravizza, L., & Costa, E.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1986-02
- Volume
- 236
- Issue
- 2
- Pages
- 307-312
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1756119985
- Cited by
- 60
- References
- 0
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maprotiline: an antidepressant with an unusual pharmacological profile. https://app.cochat.ai/papers/10.1016/s0022-3565(25)38881-6
- The paper
- Barbaccia, M. L., Ravizza, L., & Costa, E. (1986). Maprotiline: an antidepressant with an unusual pharmacological profile. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(25)38881-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.